The global castration-resistant prostate cancer (CRPC) treatment market is expected to garner a market value of US$ 11.3 Billion in 2023 and is expected to accumulate a market value of US$ 28 Billion by registering a CAGR of 9.5% in the forecast period 2023 to 2033. Growth of the castration-resistant prostate cancer (CRPC) treatment market can be attributed to increasing prevalence of the ailment and use of combination therapies to treat the ailment. The market for castration-resistant prostate cancer (CRPC) treatment registered a CAGR of 6% in the historical period 2018 to 2022
Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer that has become resistant to traditional hormone therapy (also known as androgen deprivation therapy or ADT). In CRPC, the cancer continues to grow despite low levels of testosterone in the body, which is typically the result of surgical or medical castration.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 11.3 Billion |
| Anticipated Forecast Value (2033) | US$ 28 Billion |
| Projected Growth Rate (2023 to 2033) | 9.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Castration-Resistant Prostate Cancer (CRPC) Treatment reflected a value of 6% during the historical period, 2018 to 2022.
Increasing prevalence of prostate cancer, the development of new therapies, and the rising demand for personalized medicine is driving the growth of the castration-resistant prostate cancer (CRPC) treatment market. Moreover, research and development along with technological integration for innovating medication is expected to bolster the demand for treatment of castration-resistant prostate cancer (CRPC) treatment market.
Thus, the market for Castration-Resistant Prostate Cancer (CRPC) Treatment is expected to register a CAGR of 9.5% in the forecast period 2023 to 2033.
Availability of diagnostic tools shaping landscape for CRPC market
The increasing incidence of prostate cancer, which is one of the most common cancers among men, is driving the demand for effective treatments for CRPC. The development of new treatment options, including targeted therapies, immunotherapies, and radiopharmaceuticals, has expanded the range of options available for the treatment of CRPC.
The aging population is more susceptible to prostate cancer and CRPC, and this demographic trend is increasing the demand for effective treatments for this disease. The availability of diagnostic tools such as imaging technologies, genomic testing, and liquid biopsies has improved the detection and monitoring of CRPC, which is contributing to the demand for effective treatments.
The increasing research and development activities in the field of oncology, including prostate cancer, are leading to the development of new and innovative treatments for CRPC. The government initiatives aimed at increasing awareness of prostate cancer and improving access to healthcare services are contributing to the growth of the CRPC treatment market.
Presence of different treatments creative lucrative opportunities for CRPC market
Second-line hormone therapy: This involves the use of different types of hormone therapy drugs that target different aspects of the androgen receptor pathway.
Chemotherapy: Chemotherapy drugs such as docetaxel and cabazitaxel may be used to treat CRPC.
Immunotherapy: Immune checkpoint inhibitors such as pembrolizumab and nivolumab have been approved for the treatment of certain types of CRPC.
Radiopharmaceutical therapy: Radiopharmaceuticals such as radium-223 and lutetium-177 PSMA have been approved for the treatment of CRPC that has spread to the bones.
Targeted therapy: Targeted drugs such as enzalutamide, abiraterone, and apalutamide may be used to treat CRPC by blocking specific pathways that fuel the growth of cancer cells.
Clinical trials: Participation in clinical trials of new treatments is also an option for some patients with CRPC.
Principal Consultant
Limited efficiency of treatments along with expensive nature of treatment affecting market growth
Many of the available treatment options for CRPC are expensive, and this can make them inaccessible to patients who cannot afford them or are not covered by health insurance. The side effects of many CRPC treatments, such as chemotherapy and immunotherapy, can be severe and impact a patient's quality of life. This can make it challenging for patients to tolerate the treatments and continue with their treatment plans.
While there are several treatment options available for CRPC, not all of them are effective for every patient. Some patients may not respond to certain treatments, and this can limit the efficacy of the available options. Some patients may develop resistance to the available treatments, which can make it challenging to manage their disease and prolong their survival.
Despite the advances in research and development, the underlying mechanisms of CRPC are not fully understood, and this can make it challenging to develop new and more effective treatments. Developing new treatments for CRPC can be challenging due to regulatory requirements, including the need for extensive clinical trials to demonstrate safety and efficacy. All these factors are derailing the growth of CRPC market.
Newer targeted therapies creating lucrative opportunities for CPRC treatment
The North American market for Castration-Resistant Prostate Cancer (CRPC) treatment is one of the largest markets in the world, due to the high prevalence of prostate cancer in the region and the availability of advanced healthcare infrastructure.
In terms of treatment options, chemotherapy and hormone therapy have been the mainstays of CRPC treatment in North America for many years, but newer targeted therapies such as abiraterone, enzalutamide, apalutamide, and radium-223 have also been approved for use. Immunotherapy, such as the use of immune checkpoint inhibitors, is also being investigated for CRPC treatment. Thus, North America is expected to possess 46% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
Increasing awareness of diagnosis propelling demand for CRPC treatment in Europe
The Europe CRPC treatment market is being driven by the increasing prevalence of the disease in the region, as well as the growing awareness and diagnosis of the disease. In addition, the market is being driven by the introduction of novel treatments that offer better efficacy and fewer side effects than traditional therapies.
One of the most promising developments in CRPC treatment is the use of targeted therapies. These drugs are designed to specifically target the cancer cells and limit their growth and spread, while minimizing damage to healthy cells. Targeted therapies such as enzalutamide and abiraterone have shown significant benefits in treating CRPC, leading to their approval by regulatory agencies in Europe. Thus, Europe is expected to possess 40% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Ease to administer oral medication increasing dependency to treat CRPC treatment
The oral route offers patients the convenience of taking medication in the comfort of their own homes. This is particularly beneficial for CRPC patients, who may need to take medication for extended periods of time. Oral medications can be taken without the need for hospital visits or invasive procedures, making treatment more accessible and less disruptive to a patient's daily life.
In addition, the oral route of administration can help to improve patient adherence to treatment. Patients are more likely to take their medication as prescribed when it is delivered in a convenient, easy-to-administer format. This is particularly important in the treatment of CRPC, where adherence to therapy is crucial for achieving positive treatment outcomes. Thus, by drug delivery method, oral route is expected to possess 55% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
Key players in the castration-resistant prostate cancer (CRPC) treatment market are Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC, Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc, Dendreon Corporation
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 11.3 Billion |
| Market Value in 2033 | US$ 28 Billion |
| Growth Rate | CAGR of 9.5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The Asia Pacific region is projected to emerge as a lucrative market for Castration-Resistant Prostate Cancer (CRPC) Treatment.
The growth potential of the Castration-Resistant Prostate Cancer (CRPC) Treatment market is 8% through 2033.
The high cost of treatment is likely to limit market growth.
North America is likely to generate 46% revenue in 2023.
The global market size to reach US$ 28 billion by 2033.
1. Executive Summary | Castration-Resistant Prostate Cancer (CRPC) Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033
5.3.1. Hormonal therapy
5.3.2. Chemotherapy
5.3.3. Immunotherapy
5.3.4. Radiotherapy
5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
6.3.1. Antineoplastic
6.3.2. Non-steroidal Antiandrogen
6.3.3. Corticosteroids
6.3.4. Microtubule Inhibitor
6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Delivery Method
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Drug Delivery Method , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Delivery Method , 2023 to 2033
7.3.1. Oral Route
7.3.2. Injectable Route
7.4. Y-o-Y Growth Trend Analysis By Drug Delivery Method , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Drug Delivery Method , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. MEA
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Therapy Type
10.2.3. By Drug Class
10.2.4. By Drug Delivery Method
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Therapy Type
10.3.3. By Drug Class
10.3.4. By Drug Delivery Method
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Therapy Type
11.2.3. By Drug Class
11.2.4. By Drug Delivery Method
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Therapy Type
11.3.3. By Drug Class
11.3.4. By Drug Delivery Method
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United Kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Therapy Type
12.2.3. By Drug Class
12.2.4. By Drug Delivery Method
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Therapy Type
12.3.3. By Drug Class
12.3.4. By Drug Delivery Method
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Therapy Type
13.2.3. By Drug Class
13.2.4. By Drug Delivery Method
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Therapy Type
13.3.3. By Drug Class
13.3.4. By Drug Delivery Method
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Therapy Type
14.2.3. By Drug Class
14.2.4. By Drug Delivery Method
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Therapy Type
14.3.3. By Drug Class
14.3.4. By Drug Delivery Method
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Therapy Type
15.2.3. By Drug Class
15.2.4. By Drug Delivery Method
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Therapy Type
15.3.3. By Drug Class
15.3.4. By Drug Delivery Method
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Therapy Type
16.2.3. By Drug Class
16.2.4. By Drug Delivery Method
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Therapy Type
16.3.3. By Drug Class
16.3.4. By Drug Delivery Method
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Therapy Type
17.1.2.2. By Drug Class
17.1.2.3. By Drug Delivery Method
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Therapy Type
17.2.2.2. By Drug Class
17.2.2.3. By Drug Delivery Method
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Therapy Type
17.3.2.2. By Drug Class
17.3.2.3. By Drug Delivery Method
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Therapy Type
17.4.2.2. By Drug Class
17.4.2.3. By Drug Delivery Method
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Therapy Type
17.5.2.2. By Drug Class
17.5.2.3. By Drug Delivery Method
17.5.2.4. By Distribution Channel
17.6. United Kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Therapy Type
17.6.2.2. By Drug Class
17.6.2.3. By Drug Delivery Method
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Therapy Type
17.7.2.2. By Drug Class
17.7.2.3. By Drug Delivery Method
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Therapy Type
17.8.2.2. By Drug Class
17.8.2.3. By Drug Delivery Method
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Therapy Type
17.9.2.2. By Drug Class
17.9.2.3. By Drug Delivery Method
17.9.2.4. By Distribution Channel
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Therapy Type
17.10.2.2. By Drug Class
17.10.2.3. By Drug Delivery Method
17.10.2.4. By Distribution Channel
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Therapy Type
17.11.2.2. By Drug Class
17.11.2.3. By Drug Delivery Method
17.11.2.4. By Distribution Channel
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Therapy Type
17.12.2.2. By Drug Class
17.12.2.3. By Drug Delivery Method
17.12.2.4. By Distribution Channel
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Therapy Type
17.13.2.2. By Drug Class
17.13.2.3. By Drug Delivery Method
17.13.2.4. By Distribution Channel
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Therapy Type
17.14.2.2. By Drug Class
17.14.2.3. By Drug Delivery Method
17.14.2.4. By Distribution Channel
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Therapy Type
17.15.2.2. By Drug Class
17.15.2.3. By Drug Delivery Method
17.15.2.4. By Distribution Channel
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Therapy Type
17.16.2.2. By Drug Class
17.16.2.3. By Drug Delivery Method
17.16.2.4. By Distribution Channel
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Therapy Type
17.17.2.2. By Drug Class
17.17.2.3. By Drug Delivery Method
17.17.2.4. By Distribution Channel
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Therapy Type
17.18.2.2. By Drug Class
17.18.2.3. By Drug Delivery Method
17.18.2.4. By Distribution Channel
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Therapy Type
17.19.2.2. By Drug Class
17.19.2.3. By Drug Delivery Method
17.19.2.4. By Distribution Channel
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Therapy Type
17.20.2.2. By Drug Class
17.20.2.3. By Drug Delivery Method
17.20.2.4. By Distribution Channel
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Therapy Type
17.21.2.2. By Drug Class
17.21.2.3. By Drug Delivery Method
17.21.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Therapy Type
18.3.3. By Drug Class
18.3.4. By Drug Delivery Method
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Sanofi S.A.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Johnson and Johnson
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Pfizer, Inc.
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Bayer AG
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Abbott Laboratories
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. GlaxoSmithKline PLC
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Northwest Biotherapeutics, Inc.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Active Biotech AB
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Astellas Pharma, Inc.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Dendreon Corporation
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Castration-Resistant Prostate Cancer (CRPC) Treatment Market
